BioSpace News Archive

Elastomeric respirators are the reusable tight-fitting air-purifier respirators that seal the nasal and mouth portion of the face using elastomeric material.

Albany NY, United States: The demand within the global market for bovine respiratory disease treatment has been rising on account of advancements in the field of pulmonary disease treatment, finds TMR.

Albany NY, United States: The global white biotechnology market is highly consolidated, as key players are holding 71% share in the global market, reports Transparency Market Research.

DUBAI, United Arab Emirates, The Cytomegalovirus Treatment Market is poised to grow at an impressive y-o-y of over 5.5% in 2019, as per the latest research study published by FMI.

Albany NY, United States: The global urinalysis market is marked by fierce competition among the leading players.

Albany NY, United States: The demand within the global market for pulmonary drugs has been rising on account of advancements in the field of healthcare and diagnosis, finds Transparency Market Research.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports promising results from its phase 2a maintenance trial in rheumatoid arthritis after one year of continued daily treatment with 50mg ABX464.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor.

Everest Medicines announced that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1, evaluating cefepime-taniborbactam, an investigational new drug, versus meropenem as a potential treatment for hospitalized adult patients with complicated urinary tract infections, including acute pyelonephritis.

LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the fourth quarter and full year ended December 31, 2021.